313 related articles for article (PubMed ID: 15720370)
1. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles.
Oades RD; Sadile AG; Sagvolden T; Viggiano D; Zuddas A; Devoto P; Aase H; Johansen EB; Ruocco LA; Russell VA
Dev Sci; 2005 Mar; 8(2):122-31. PubMed ID: 15720370
[TBL] [Abstract][Full Text] [Related]
2. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
Wilens TE
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
[TBL] [Abstract][Full Text] [Related]
3. The neuropsychopharmacology of attention-deficit/hyperactivity disorder.
Pliszka SR
Biol Psychiatry; 2005 Jun; 57(11):1385-90. PubMed ID: 15950012
[TBL] [Abstract][Full Text] [Related]
4. Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD).
Oades RD
Prog Brain Res; 2008; 172():543-65. PubMed ID: 18772050
[TBL] [Abstract][Full Text] [Related]
5. Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder.
van der Kooij MA; Glennon JC
Neurosci Biobehav Rev; 2007; 31(4):597-618. PubMed ID: 17316796
[TBL] [Abstract][Full Text] [Related]
6. Neurobiology of ADHD.
Tripp G; Wickens JR
Neuropharmacology; 2009 Dec; 57(7-8):579-89. PubMed ID: 19627998
[TBL] [Abstract][Full Text] [Related]
7. Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro.
Yoon SY; dela Peña I; Kim SM; Woo TS; Shin CY; Son KH; Park H; Lee YS; Ryu JH; Jin M; Kim KM; Cheong JH
Arch Pharm Res; 2013 Jan; 36(1):134-40. PubMed ID: 23371806
[TBL] [Abstract][Full Text] [Related]
8. Attention deficit and hyperactivity disorder: review of genetic association studies.
Galili-Weisstub E; Segman RH
Isr J Psychiatry Relat Sci; 2003; 40(1):57-66. PubMed ID: 12817670
[TBL] [Abstract][Full Text] [Related]
9. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
Prince J
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S39-45. PubMed ID: 18480676
[TBL] [Abstract][Full Text] [Related]
10. Catecholamines in attention-deficit hyperactivity disorder: current perspectives.
Pliszka SR; McCracken JT; Maas JW
J Am Acad Child Adolesc Psychiatry; 1996 Mar; 35(3):264-72. PubMed ID: 8714313
[TBL] [Abstract][Full Text] [Related]
11. Cerebellar neurotransmission in attention-deficit/hyperactivity disorder: does dopamine neurotransmission occur in the cerebellar vermis?
Glaser PE; Surgener SP; Grondin R; Gash CR; Palmer M; Castellanos FX; Gerhardt GA
J Neurosci Methods; 2006 Feb; 151(1):62-7. PubMed ID: 16451810
[TBL] [Abstract][Full Text] [Related]
12. A review of the biological bases of ADHD: what have we learned from imaging studies?
Durston S
Ment Retard Dev Disabil Res Rev; 2003; 9(3):184-95. PubMed ID: 12953298
[TBL] [Abstract][Full Text] [Related]
13. The usefulness of the spontaneously hypertensive rat to model attention-deficit/hyperactivity disorder (ADHD) may be explained by the differential expression of dopamine-related genes in the brain.
Li Q; Lu G; Antonio GE; Mak YT; Rudd JA; Fan M; Yew DT
Neurochem Int; 2007 May; 50(6):848-57. PubMed ID: 17395336
[TBL] [Abstract][Full Text] [Related]
14. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses.
Genro JP; Kieling C; Rohde LA; Hutz MH
Expert Rev Neurother; 2010 Apr; 10(4):587-601. PubMed ID: 20367210
[TBL] [Abstract][Full Text] [Related]
15. Different adaptations in ventral tegmental area dopamine neurons in control and ethanol exposed rats after methylphenidate treatment.
Shen RY; Choong KC
Biol Psychiatry; 2006 Apr; 59(7):635-42. PubMed ID: 16199009
[TBL] [Abstract][Full Text] [Related]
16. Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling.
Viggiano D; Vallone D; Sadile A
Neural Plast; 2004; 11(1-2):97-114. PubMed ID: 15303308
[TBL] [Abstract][Full Text] [Related]
17. Neurobiology of animal models of attention-deficit hyperactivity disorder.
Russell VA
J Neurosci Methods; 2007 Apr; 161(2):185-98. PubMed ID: 17275916
[TBL] [Abstract][Full Text] [Related]
18. Rodent models of attention-deficit/hyperactivity disorder.
Sagvolden T; Russell VA; Aase H; Johansen EB; Farshbaf M
Biol Psychiatry; 2005 Jun; 57(11):1239-47. PubMed ID: 15949994
[TBL] [Abstract][Full Text] [Related]
19. [Neuropsychological assessment of the effectiveness of OROS-methylphenidate in attention deficit hyperactivity disorder].
Rubio-Morell B; Martín-González R; Herreros-Rodríguez O; González-Pérez P; Hernández-Exposito S; Quintero-Fuentes I; Gracia-Marco R
Rev Neurol; 2008 May 16-31; 46(10):602-8. PubMed ID: 18465700
[TBL] [Abstract][Full Text] [Related]
20. The dopamine transporter: role in neurotoxicity and human disease.
Bannon MJ
Toxicol Appl Pharmacol; 2005 May; 204(3):355-60. PubMed ID: 15845424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
